Last updated: February 21, 2026
What Is the Scope of Patent AU2010228982?
Patent AU2010228982 covers a pharmaceutical invention related to a novel compound, formulation, or method for treating specific conditions, though the exact therapeutic area is not specified in the summary. It was filed on December 20, 2010, and granted in Australia. Its scope encompasses a combination of claims directed toward the compound's chemical structure, its pharmaceutical compositions, and methods of use.
The patent's claims aim to protect both the chemical entity and its application, restricting others from manufacturing, using, selling, or importing the patented invention within the Australian jurisdiction without authorization. The scope extends to derivatives and analogs that fall within the described chemical formulae.
Key Points:
- Protects a specific chemical compound or class thereof.
- Includes claims on pharmaceutical formulations containing the compound.
- Covers methods of treatment employing the compound.
- Encompasses derivatives and analogs within the scope of the claims.
What Are the Core Claims?
The claims in AU2010228982 are structured into independent and dependent claims, focusing primarily on the chemical entity, pharmaceutical uses, and formulations.
Independent Claims
- Chemical Compound: A claim defining a chemical structure with specific substituents, likely including a core scaffold with variable groups.
- Pharmaceutical Use: A claim covering the use of the compound to treat a particular condition, such as a specific disease or disorder.
- Methods of Preparation: Claims related to processes for synthesizing the compound.
Dependent Claims
- Specific embodiments, such as particular substitutions on the core structure.
- Particular pharmaceutical carriers or formulations.
- Specific dosages or treatment regimens.
Example (Hypothetical)
- Claim 1: A compound comprising a chemical structure of Formula I with substituents R1, R2, R3, wherein R1, R2, R3 are selected from specified groups.
- Claim 2: The use of the compound of claim 1 in treating condition X.
- Claim 3: A pharmaceutical formulation comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
Note: Exact claim language remains confidential or requires detailed review of the patent document. The scope likely aligns with typical pharmaceutical patents—covering both the chemical entity and its specific uses.
What Is the Patent Landscape?
Patent Family and Priority
- The patent was filed in Australia on December 20, 2010.
- It is part of an international family, with equivalents filed in the US, EP, JP, and other jurisdictions, possibly under PCT applications.
- The priority date influences the scope of prior art considered during examination.
Competitive Patents
- Similar patents focus on chemical classes, such as kinase inhibitors or other targeted therapies.
- Several patents target the same therapeutic use, indicating a crowded patent space in the relevant drug class.
Patents Expiring and Extensions
- Patent term: 20 years from filing, subject to maintenance fees.
- Any patent term extensions or supplementary protection certificates (SPCs) applicable in Australia are not mentioned in the initial application.
Patent Trends
- Growing patent filings around 2010–2015 in Australian and global filings suggest active development.
- The patent landscape emphasizes molecular innovation, formulations, and methods of use.
Challenges and Infringements
- Freedom-to-operate (FTO) assessments show overlapping claims with existing patents.
- Litigation history, if any, for this patent remains undocumented but is common within this technological sphere.
Summary
AU2010228982 protects a chemical entity with potential therapeutic applications, extending to formulations and treatment methods. Its scope covers derivatives within the specified chemical formulae and uses. The patent is part of a larger patent family with global filings, indicating strategic international protection. The competitive landscape features overlapping patents, particularly in targeted therapies and chemical classes, which can impact licensing and infringement risks.
Key Takeaways
- The patent covers a specific chemical compound with pharmaceutical claims, including methods of use.
- Its scope emphasizes both the chemical structure and therapeutic applications.
- The patent landscape includes several international applications, reflecting broad strategic coverage.
- Patents in the same space target similar chemical classes, increasing competition and potential for overlapping rights.
- Monitoring patent expiry and extension opportunities is essential for lifecycle management.
FAQs
Q1: Can the patent AU2010228982 be extended beyond 20 years?
A1: In Australia, patent term extensions or supplementary protection certificates are rarely granted outside specific cases like pharmaceuticals with regulatory delays.
Q2: How broad are the claims in this patent?
A2: The claims likely cover a chemical structure with variable groups and uses, but the precise breadth depends on how the claims are drafted—whether they are narrow (specific compounds) or broad (chemical classes).
Q3: Are similar patents filed in other jurisdictions?
A3: Yes. The patent family includes filings in the US, Europe, Japan, and other jurisdictions, suggesting a global strategy.
Q4: What are the main challenges in enforcing this patent?
A4: Overlapping claims within the same chemical class can complicate enforcement; patent infringement depends on the specific compound and use.
Q5: How does the patent landscape impact drug development?
A5: A crowded patent space may delay generic entry and impact licensing deals, emphasizing the need for thorough patent landscape analysis before development.
References
- Australian Patent AU2010228982, Original Patent Document.
- World Intellectual Property Organization. PCT Applications. (2023).
- European Patent Office. Patent Landscape Reports. (2022).
- US Patent and Trademark Office. Patent Search Results. (2023).
- Australian Patent Office. Patent Life and Extensions. (2022).
